Oncotelic's Injectable Everolimus Formulation Receives Clinical Trial Clearance with Potential to Transform Breast Cancer Treatment
TL;DR
Oncotelic Therapeutics' Sapu003 technology could provide a competitive advantage by dramatically increasing drug bioavailability from 10% to near 100% for breast cancer treatment.
Oncotelic's Deciparticles technology creates sub-20nm nanoparticles that enable injectable Everolimus to achieve 80-100% bioavailability compared to 10% with oral administration.
This advancement could significantly improve breast cancer treatment outcomes by delivering more consistent and effective medication to patients in need.
Oncotelic's nanoparticle technology transforms a common cancer drug into an injectable form that could work up to ten times more effectively than current oral versions.
Oncotelic Therapeutics Inc. has achieved a significant milestone with the clearance to begin Phase 1 clinical trials for Sapu003, an injectable formulation of Everolimus marketed as Afinitor(R). This development represents a potential breakthrough in breast cancer treatment through the company's proprietary Deciparticles(TM) technology, which enables the creation of sub-20nm nanoparticles designed to dramatically improve drug bioavailability.
The clinical trial authorization comes through Sapu Nano, part of Oncotelic's GMP Bio joint venture established with Dragon Overseas Capital Limited. Preclinical studies have demonstrated remarkable results, showing that Sapu003 could increase the bioavailability of Everolimus from approximately 10% when administered as an oral pill to anywhere from 80% to 100% when delivered as an injectable formulation. This substantial improvement in bioavailability could translate to significantly enhanced treatment outcomes for breast cancer patients.
The implications of this technological advancement extend far beyond simple dosage improvements. Higher bioavailability typically means drugs can achieve better, faster, and more consistent efficacy, potentially reducing treatment durations and improving patient quality of life. For breast cancer patients specifically, this could mean more predictable treatment responses and potentially better survival outcomes. The pharmaceutical industry as a whole stands to benefit from this nanoparticle technology platform, which could be applied to other drugs facing bioavailability challenges.
Oncotelic Therapeutics, trading as OTCQB: OTLC, operates as a clinical-stage biopharmaceutical company with a diversified pipeline spanning oncology, immunotherapy, neurodegeneration, and rare diseases. In a recent interview available through the BioMedWire podcast, Chairman and CEO Dr. Vuong Trieu emphasized the company's strategic focus on de-risked, late-stage assets and accelerating development through efficient regulatory pathways. This approach positions the company to potentially bring innovative treatments to market more rapidly than traditional development models.
The successful development of Sapu003 could establish new standards for drug delivery in oncology and beyond. The Deciparticles(TM) technology platform represents a significant advancement in nanomedicine, with potential applications across multiple therapeutic areas where poor bioavailability limits treatment effectiveness. As the Phase 1 trial progresses, the medical community will be watching closely for clinical validation of the promising preclinical results that suggest a fundamental improvement in how established cancer drugs can be delivered to patients.
Curated from InvestorBrandNetwork (IBN)
